7.2 Surgical Oncology, Perioperative Care & Reconstruction

Surgical Oncology, Perioperative Care & Reconstruction

Surgical oncology remains the oldest and most definitive curative modality for the majority of solid tumors. Beyond primary curative resection, surgical interventions are integral across the entire cancer care continuum—from initial tissue diagnosis and staging to palliation of oncologic emergencies and complex reconstruction. For the Advanced Practice Registered Nurse (APRN), effective surgical oncology management requires synthesizing surgical principles, pathologic staging, multimodal sequencing timing, perioperative optimization, and postoperative complication surveillance.

---

1. Surgical Roles Across the Cancer Continuum

Oncologic surgical procedures are broadly categorized by their primary clinical intent:

---

2. Pathologic Margins & Nodal Staging Principles

Pathologic Surgical Margins

The primary goal of curative surgical oncology is achieving en bloc resection of the primary tumor with clear, micro- and macroscopically negative anatomical margins.

• R0 Resection: Complete tumor resection with negative microscopic margins (no cancer cells at the inked surgical edge). Represents the prerequisite for surgical cure.
• R1 Resection: Microscopic residual tumor identified at the resected margin by the pathologist. Associated with high rates of local recurrence; requires consideration of re-excision or adjuvant radiation/systemic therapy.
• R2 Resection: Macroscopic (gross) residual tumor left behind postoperatively. Indicates incomplete resection; converts surgical intent to debulking or palliation.

Tumor-Specific Margin Guidelines

• Cutaneous Melanoma: Margin size dictated strictly by Breslow thickness:
  • Melanoma in situ: 0.5 cm margin.
  • Breslow $< 1.0 ext{ mm}$: 1.0 cm margin.
  • Breslow $1.01–2.0 ext{ mm}$: 1.0 to 2.0 cm margin.
  • Breslow $> 2.0 ext{ mm}$: 2.0 cm margin.
• Breast Conservation Therapy (Lumpectomy):
  • Invasive Breast Cancer: "No ink on tumor" (no tumor cells directly touching the inked margin).
  • Ductal Carcinoma in Situ (DCIS): Minimum 2.0 mm clear margin.
• Colon Cancer: Minimum 5.0 cm clear proximal and distal bowel margins along with en bloc resection of the draining mesentery containing at least 12 regional lymph nodes.

Sentinel Lymph Node Biopsy (SLNB) vs. Complete Dissection

• SLNB Rationale: The sentinel lymph node is the first node(s) receiving lymphatic drainage from a primary tumor. Injecting radiocolloid (Technetium-99m) and/or isosulfan blue dye identifies sentinel nodes. If the sentinel node is pathologically negative, the remainder of the nodal basin is negative with $>95%$ certainty.
• Clinical Benefit: Omitting Complete Lymph Node Dissection (CLND) in sentinel-negative patients drastically reduces upper/lower extremity chronic lymphedema, wound seromas, sensory paresthesias, and chronic pain while maintaining equivalent overall survival in breast cancer and melanoma.

---

3. Multimodal Integration & Perioperative Timing

Modern solid tumor management relies on integrating surgery with neoadjuvant (preoperative) and adjuvant (postoperative) systemic therapy and radiation.

Neoadjuvant Therapy (Systemic / RT) 
  ├── Purpose: Tumor downstaging, early micrometastatic control, organ preservation
  └── Surgical Hold Window: Allow bone marrow & tissue recovery (typically 4-6 weeks)
        │
        ▼
Definitive Surgical Resection (R0 Goal)
  └── Wound Healing & Recovery Window: 4 to 6 weeks
        │
        ▼
Adjuvant Therapy (Chemotherapy / RT / Endocrine)
  └── Purpose: Eradicate microscopic residual disease

Critical Anti-VEGF & Targeted Drug Hold Times

Administering targeted anti-angiogenic agents or cytotoxic chemotherapy too close to surgical procedures compromises physiological wound healing and increases catastrophic perioperative morbidity:

• Bevacizumab (Anti-VEGF Monoclonal Antibody): Inhibits endothelial repair and collagen synthesis. Must be held for at least 4 to 6 weeks prior to elective surgery and held for at least 4 to 6 weeks postoperatively until all surgical incisions are completely healed. Premature surgery increases risks of wound dehiscence, fatal surgical hemorrhage, and bowel perforation.
• Tyrosine Kinase Inhibitors (TKIs): VEGFR-TKI agents (e.g., sunitinib, pazopanib) should be held 3 to 7 days pre- and postoperatively.
• Cytotoxic Chemotherapy: Usually held 3 to 4 weeks prior to surgery to allow complete hematologic recovery (absolute neutrophil count $>1.5 imes 10^9/ ext{L}$, platelets $>100 imes 10^9/ ext{L}$). Postoperative adjuvant chemotherapy should ideally initiate within 4 to 8 weeks after surgery once healing is verified.

---

4. APRN Perioperative Management & ERAS Protocols

Enhanced Recovery After Surgery (ERAS)

ERAS protocols represent evidence-based multimodal perioperative pathways designed to attenuate the surgical stress response, maintain physiological homeostasis, and accelerate recovery:

• Preoperative: Avoid prolonged fasting (allow clear fluids up to 2 hours pre-op), carbohydrate loading drinks, selective bowel preparation, preoperative nutritional optimization.
• Intraoperative: Goal-directed fluid therapy (avoid fluid overload), short-acting anesthetic agents, normothermia maintenance, opioid-sparing multimodal analgesia (regional blocks, acetaminophen, NSAIDs/celecoxib, gabapentinoids).
• Postoperative: Early removal of urinary catheters and surgical drains, early oral refeeding, early ambulation within 24 hours post-op, aggressive VTE prophylaxis.

Postoperative Complication Surveillance

1. Surgical Site Infection (SSI): Erythema, purulent drainage, localized warmth, fever $>38.0^\circ ext{C}$. Obtain wound cultures and initiate targeted antibiotic therapy.
2. Wound Dehiscence & Evisceration: Separation of surgical wound layers. Risk factors include obesity, malnutrition, corticosteroids, prior radiation, and bevacizumab. Evisceration requires immediate application of sterile saline-soaked dressings and emergency surgical exploration.
3. Anastomotic Leak: Occurs following gastrointestinal resections (typically post-op days 4–7). Clinical signs include persistent tachycardia, fever, severe abdominal pain, peritonitis, purulent/fecal drain output, and acute sepsis. Emergency CT scan with oral/IV contrast is diagnostic.
4. Venous Thromboembolism (VTE): High risk in oncology surgical patients. Prophylaxis requires mechanical compression devices combined with low-molecular-weight heparin (LMWH, e.g., enoxaparin 40 mg SC daily) continued for 28 days postoperatively for high-risk abdominal/pelvic cancer resections.

---

5. Reconstruction & Oncologic Rehabilitation

Reconstructive surgical oncology restores form and function following extensive tissue extirpation:

• Breast Reconstruction: Autologous tissue transfer flaps (Deep Inferior Epigastric Perforator [DIEP] flap, Transverse Rectus Abdominis Myocutaneous [TRAM] flap, Latissimus Dorsi flap) vs. prosthetic implant-based reconstruction (tissue expanders followed by permanent implants).
• Lymphedema Prevention & Surgical Management: In patients with severe secondary lymphedema refractory to conservative compression therapy, microsurgical techniques such as Lymphaticovenous Anastomosis (LVA) (bypassing obstructed lymphatics into subdermal veins) or Vascularized Lymph Node Transfer (VLNT) can significantly improve fluid drainage.